Shares of vaccine makers closed lower Thursday amid reports that President-elect Donald Trump was set to nominate vaccine ...

Shares of BioNTech (BNTX) and Novavax (NVAX) closed with losses of 7%, while Moderna's stock (MRNA) shed 6%. Vaxcyte (PCVX) dropped 4%, and Pfizer (PFE) pulled back 3%. The sizeable declines in these ...

Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...

In this article, we will discuss the 12 High Growth Large Cap Stocks to Buy Now. BlackRock highlighted that its portfolio ...

On the other hand, Moderna Inc (NASDAQ: MRNA) posted a surprise profit and higher than expected revenue following the launch ...

Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024 Solid financial position enables Vaxart to attain multiple regulatory and ...

Pfizer and Moderna are hustling to develop an mRNA bird flu vaccine, the same technology used in the companies' respective ...

Avidity Biosciences stock surges on expansion of pipeline targeting rare genetic cardiomyopathies and improvements in siRNA ...

Novavax, Inc. (NASDAQ:NVAX) Q3 2024 Earnings Call Transcript November 12 ... Novavax is demonstrating the ability to compete ...

Wave Life Sciences Ltd. (NASDAQ:WVE) Q3 2024 Earnings Call Transcript November ... These targets include PNPLA3 where we are ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good afternoon and welcome everyone to the GeoVax Third Quarter 2024 Corporate Update Call. My name is Michelle and I will facilitate today ...

We are committed to advancing its research and development in combination with our investigational mRNA vaccines, targeted therapies, and immunomodulators with the aim of enhancing outcomes for ...